India's pharmaceutical exports to Argentina are predominantly concentrated in antiretroviral (ARV) therapies, reflecting Argentina's substantial demand for HIV/AIDS treatment. The top export, a combination tablet of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate, accounts for 6.2% of total exports, with 90,000 units (2.7 million tablets) valued at $834,000. Other significant exports include Tacrolimus (4.5%) and Efavirenz, Emtricitabine, and Tenofovir (3.0%), underscoring the critical need for immunosuppressants and ARVs in Argentina. This dominance aligns with Argentina's healthcare priorities, as the country has a high prevalence of HIV/AIDS, necessitating a steady supply of these essential medications.
The prominence of these therapeutic areas is further supported by Argentina's healthcare infrastructure, which emphasizes the treatment of infectious diseases, particularly HIV/AIDS. The National Administration of Drugs, Food and Medical Technology (ANMAT) has streamlined the approval processes for such medications, facilitating their availability. Additionally, the Argentine pharmaceutical market is characterized by a high concentration of marketing, with 90% of products distributed through only five intermediaries, indicating a structured and efficient distribution system for these critical drugs.
